FORMA THERAPEUTICS HOLDINGS (FMTX)

Company Profile

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 189 full-time employees. The company went IPO on 2020-06-16. The firm is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers. Its pipeline consists of six product candidates. Its product candidates include etavopivat, FT-7051, Olutasidenib- Acute Myeloid Leukemia IDH1m inhibitor, and Olutasidenib Glioma IDH1m inhibitor. Its lead product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy for the treatment of sickle cell disease (SCD), and other hemoglobinopathies. Its product candidate, FT-7051, is an inhibitor of CREB-binding protein/E1A binding protein p300, or CBP/p300 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Olutasidenib is an oral, selective small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes.

Company Info

FORMA THERAPEUTICS HOLDINGS

300 North Beacon Street, Suite 501

Watertown MASSACHUSETTS 02472

P: 16176791970.0

CEO: Frank D. Lee

Employees: 189

Website: https://ir.formatherapeutics.com/